Cannabinoid · Muscle Relaxant
Also known as Sativex, Cannabis extract, Dronabinol/Cannabidiol
Nabiximols contains Δ9-THC and CBD as its active principles. Cannabidiol (CBD) is a low-affinity agonist at CB1/CB2 receptors. Additionally, CBD binds to other (orphan) GPCRs and can influence serotonin and opioid signaling.
Manufacturer advises use only if potential benefit outweighs risks.
Avoid—present in milk.
Potential for nabiximols to increase levels of other drugs metabolized by CYP3A4. Increased THC and CBD exposure.
If the doses of drugs in these classes are increased or decreased when a patient is receiving nabiximols, their dosing should be reviewed.
Source: G&G 14e · p514
Decreased THC and CBD exposure, potentially reducing nabiximols efficacy.
If the doses of drugs in these classes are increased or decreased when a patient is receiving nabiximols, their dosing should be reviewed.
Source: G&G 14e · p514
Potential for nabiximols to increase levels of other drugs metabolized by CYP3A4. Increased THC and CBD exposure.
If the doses of drugs in these classes are increased or decreased when a patient is receiving nabiximols, their dosing should be reviewed.
Source: G&G 14e · p514
Potential for nabiximols to increase levels of other drugs metabolized by CYP3A4. Increased THC and CBD exposure.
If the doses of drugs in these classes are increased or decreased when a patient is receiving nabiximols, their dosing should be reviewed.
Source: G&G 14e · p514
Potential for nabiximols to increase levels of other drugs metabolized by CYP3A4. Increased THC and CBD exposure.
If the doses of drugs in these classes are increased or decreased when a patient is receiving nabiximols, their dosing should be reviewed.
Source: G&G 14e · p514
Decreased THC and CBD exposure, potentially reducing nabiximols efficacy.
If the doses of drugs in these classes are increased or decreased when a patient is receiving nabiximols, their dosing should be reviewed.
Source: G&G 14e · p514
Potential for nabiximols to increase levels of other drugs metabolized by CYP3A4. Increased THC and CBD exposure.
If the doses of drugs in these classes are increased or decreased when a patient is receiving nabiximols, their dosing should be reviewed.
Source: G&G 14e · p514
Decreased THC and CBD exposure, potentially reducing nabiximols efficacy.
If the doses of drugs in these classes are increased or decreased when a patient is receiving nabiximols, their dosing should be reviewed.
Source: G&G 14e · p514
Potential for nabiximols to increase levels of other drugs metabolized by CYP3A4. Increased THC and CBD exposure.
If the doses of drugs in these classes are increased or decreased when a patient is receiving nabiximols, their dosing should be reviewed.
Source: G&G 14e · p514
Decreased THC and CBD exposure, potentially reducing nabiximols efficacy.
If the doses of drugs in these classes are increased or decreased when a patient is receiving nabiximols, their dosing should be reviewed.
Source: G&G 14e · p514
Potential for nabiximols to increase levels of other drugs metabolized by CYP3A4. Increased THC and CBD exposure.
If the doses of drugs in these classes are increased or decreased when a patient is receiving nabiximols, their dosing should be reviewed.
Source: G&G 14e · p514
Potential for nabiximols to increase levels of other drugs metabolized by CYP3A4. Increased THC and CBD exposure.
If the doses of drugs in these classes are increased or decreased when a patient is receiving nabiximols, their dosing should be reviewed.
Source: G&G 14e · p514
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: Goodman & Gilman 14e, Katzung·Verified: 2026-05-13 · House clinical team